Biotinylated Polymer-Ruthenium Conjugates: In Vitro and In Vivo Studies in a Triple-Negative Breast Cancer Model.

ABSTRACT: The need for new therapeutic approaches for triple-negative breast cancer is a clinically relevant problem that needs to be solved. Using a multi-targeting approach to enhance cancer cell uptake, we synthesized a new family of ruthenium(II) organometallic complexes envisaging simultaneous active and passive targeting, using biotin and polylactide (PLA), respectively. All compounds with the general formula, [Ru(η⁵-CpR)(P)(2,2'-bipy-4,4'-PLA-biotin)][CF₃SO₃], where R is -H or -CH₃ and P is P(C₆H₅)₃, P(C₆H₄F)₃ or P(C₆H₄OCH₃)₃, were tested against triple-negative breast cancer cells MDA-MB-231 showing IC₅₀ values between 2.3-14.6 µ

SUBMITTER: Corte-Real L 

PROVIDER: S-EPMC9315599 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature